| Similar Articles |
|---|
 |
The Motley Fool
December 20, 2004
Brian Gorman |
Cambridge Antibody's Underdog Story Cambridge Antibody's legal success against Abbott Laboratories is a sign of the biotech industry's continued maturation. Cambridge Antibody's stock rocketed 14% on the news of its win.   |
The Motley Fool
November 23, 2004
Brian Gorman |
AstraZeneca Buys Into Cambridge Antibody Cambridge Antibody scored a new alliance, although the deal threatens to make it a house divided. |
The Motley Fool
February 17, 2010
Brian Orelli |
$1.24 Billion Deal. Shares Fall 9%. That Makes Sense. Rigel Pharmaceuticals signed up AstraZeneca to take over development of its phase 2 rheumatoid arthritis drug, R788, with more than $1.24 billion in potential payments, and the shares fell more than 9%. |
The Motley Fool
March 4, 2011
Brian Orelli |
Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors. |
Chemistry World
March 15, 2011
Sarah Houlton |
Benlysta breaks 50 year Lupus drug drought The first new treatment for lupus erythematosus in half a century has been approved by the US Food and Drug Administration |
The Motley Fool
November 8, 2010
Brian Orelli |
No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
BusinessWeek
October 18, 2004
Catherine Arnst |
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma |
The Motley Fool
June 15, 2010
Brian Orelli |
Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer. |
The Motley Fool
July 27, 2006
Stephen D. Simpson |
AstraZeneca Needs a Rest The stock isn't too expensive, but it's no longer a bargain. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
June 16, 2010
Brian Orelli |
Double-Digit Rise on Doubling Its Cash Neurocrine Biosciences is seeing a nice boost to its stock price today -- some 14% -- after Abbott Labs agreed to license its endometriosis treatment, elagolix, and any future follow-on products. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. |
The Motley Fool
July 30, 2010
Cliff D'Arcy |
Which Is the Better Big Pharma? AstraZeneca is having a good 2010 -- and its shares are enjoying a great run, too. Here's how it compares to GlaxoSmithKline. |
The Motley Fool
April 24, 2007
Brian Lawler |
MedImmune Not Immune to Takeovers MedImmune shops itself to AstraZeneca. MedImmune investors appear to be getting a pretty sweet deal. |
The Motley Fool
February 26, 2010
Brian Orelli |
Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue. |
The Motley Fool
September 6, 2011
Brian Orelli |
Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game? |
The Motley Fool
October 20, 2011
Brian Orelli |
Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other. |
Chemistry World
July 25, 2006
Bea Perks |
Clinical Chaos Under Scrutiny Clinical trials of new drugs need to be tightened up, according to an expert group convened in the aftermath of UK trials that left six people fighting for their lives. |
Chemistry World
August 27, 2014
Phillip Broadwith |
Clinical collaborations drive cancer immunotherapy A joint clinical trial agreement between Merck & Co and Pfizer is the latest in a rather tangled web of tie-ups between companies with cancer drugs that harness patients' immune systems. |
The Motley Fool
December 28, 2005
Stephen D. Simpson |
AstraZeneca, Reloaded In an attempt to shore up a soft pipeline, AstraZeneca has gotten very busy looking for partners. Investors, this is not the most attractive stock in the sector, but not a horrible pick, either. |
The Motley Fool
April 13, 2011
Brian Orelli |
Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients. |
The Motley Fool
February 2, 2006
Stephen D. Simpson |
AstraZeneca: Of Patents and Pipelines Losing Toprol-XL would be a blow, but not a fatal one. So what to do with AstraZeneca's stock? It might not be as cheap as Pfizer or Abbott Labs, but if the pipeline works out, it still seems like there's money to be made here. |
The Motley Fool
May 4, 2006
Stephen D. Simpson |
AstraZeneca Snuffs Out Galida Will any of the new dual-PPAR drugs make it to the market? Here's another good reminder for pharmaceutical and biotech investors that you shouldn't count your chickens until the FDA has let them hatch. |
The Motley Fool
October 26, 2006
Brian Lawler |
Market Rejects AstraZeneca's Remedy Investors pummel the pharmaceutical firm, despite its impressive results. |
The Motley Fool
December 29, 2009
Brian Orelli |
Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others. |
Chemistry World
April 4, 2013
Phillip Broadwith |
Regeneron expands, creating 400 new jobs US biotech Regeneron has announced that it will expand its corporate headquarters and laboratories in Tarrytown. |
The Motley Fool
May 21, 2009
Robert Steyer |
The AstraZeneca Dilemma Can AstraZeneca produce enough new drugs to offset a series of upcoming patent expirations? |
The Motley Fool
June 22, 2011
Brian Orelli |
In-Licensing to the Rescue Abbott's latest deal could help shore things up. |
The Motley Fool
February 25, 2008
Brian Orelli |
The Biologic That Keeps on Giving Just a month after Abbott Laboratories receives a fifth approval for its anti-inflammatory Humira, the FDA approved the biotech drug to treat yet another disease. |
The Motley Fool
December 4, 2008
Brian Orelli |
Poor Pozen It's not often that you see a drug developer release data from two positive phase 3 trials for its lead pipeline compound and see its shares fall more than 4%, but that's what happened to Pozen. |
The Motley Fool
January 27, 2011
Brian Orelli |
Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out. |
The Motley Fool
April 12, 2004
Brian Gorman |
Abbott Not Rewarded Abbott Laboratories first-quarter earnings news was positive, but investors didn't react enthusiastically. |
The Motley Fool
October 20, 2005
Brian Gorman |
Amgen's Drive to Diversify The drugmaker pulled in impressive results with its current portfolio, but a drug in late-stage testing could make the company even more attractive to investors. |
The Motley Fool
January 12, 2005
Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
The Motley Fool
June 28, 2010
Luke Timmerman |
Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system. |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
BusinessWeek
December 29, 2010
Kelley & Cortez |
AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs. |
The Motley Fool
May 3, 2010
Brian Orelli |
While You Were Reveling in Dendreon's Win The FDA has approved Vimovo, an arthritis drug from Pozen and AstraZeneca, and Bristol-Myers Squibb also got a decision from the FDA, but it wasn't the positive kind. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
July 9, 2010
Ryan McBride |
Novartis Test-Drives Biotech Startup Adimab's Drug Discovery Engine More collaborations in Big Pharma. |
Chemistry World
October 21, 2011
Sarah Houlton |
Abbott Splits to Set Pharma Portfolio Free Abbott Laboratories is to be split in two and claims the aim is to strengthen the outlook for growth and shareholder returns. |
BusinessWeek
January 29, 2007
Arlene Weintraub |
More Merger Mania Ahead For Pharma The scramble for new drugs is keeping companies on the prowl. |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
The Motley Fool
March 9, 2009
Brian Orelli |
Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth. |
Chemistry World
December 22, 2011
Sarah Houlton |
Pharma braces for patent cliff impact It remains to be seen quite how far Lipitor sales will fall. Ranbaxy has six months of exclusivity for generic competition. |
The Motley Fool
January 27, 2004
Jeff Hwang |
Merck in the Balance These are troubled times for Merck. Restructuring charges, Zocor sales woes, and a new distribution program hamper earnings. |
The Motley Fool
April 22, 2011
Sean Williams |
Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings. |
